TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28619111

Group type: EXPERIMENTAL
Intervention: Two-minute disconnection technique with a double-lumen tube (DLT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional one-lung ventilation (OLV) method
Number of subjects: 50
Study: 27165949

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin
Number of subjects: 14464

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 14464
Study: 25156269

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d, every night for ≥6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 120
Study: 21842996

Group type: EXPERIMENTAL
Intervention: Subliminal priming of negative relationships
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal priming of ambivalent ties (high in positivity and negativity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subliminal priming of indifferent relationships
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subliminal priming of supportive relationships
Number of subjects: 0
Study: 19641356

Group type: EXPERIMENTAL
Intervention: Percutaneous posterior tibial nerve stimulation (PTNS)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 89
Study: 17438343

Group type: EXPERIMENTAL
Intervention: Behavioral family intervention (BFI) - more intensive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral family intervention (BFI) - observed mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral family intervention (BFI) - observed mothers in more intensive intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 0
Study: 16618008

Group type: EXPERIMENTAL
Intervention: Hallucination-focused integrative treatment (HIT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine treatment (RT)
Number of subjects: 63
Study: 12202967

Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal, 40 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Arousal version of the slide show
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral version of the slide show
Number of subjects: 60
Study: 10702882

Group type: EXPERIMENTAL
Intervention: Single oral doses of cilostazol (50 to 200 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Repeated oral administration of cilostazol (100 mg every 12 hours)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Single oral doses of cilostazol (50 to 200 mg) and repeated doses (100 mg every 12 hours)
Number of subjects: 46
Study: 8566601

Group type: EXPERIMENTAL
Intervention: Ligation plus sclerotherapy (1 mL 1.5% tetradecyl injected just above each band)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ligation alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ligation plus sclerotherapy
Number of subjects: 41
Study: 1909152

Group type: EXPERIMENTAL
Intervention: Intermittent transdermal glyceryl trinitrate (mean dose 18.2 mg over approximately 16 hours)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Continuous treatment with 10 mg per 24 hours of transdermal glyceryl trinitrate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 6688154

Group type: EXPERIMENTAL
Intervention: Profile group (computerized drug profiles)
Number of subjects: 6186

Group type: COMPARATOR
Intervention: No-profile group (control)
Number of subjects: 6186
Study: 31910101

Group type: EXPERIMENTAL
Intervention: Vitamin D 70 μg (2800 IU)/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-thyroid medication (ATD)
Number of subjects: 0
Study: 31132509

Group type: COMPARATOR
Intervention: 10 Hz‐rTMS
Number of subjects: 16

Group type: COMPARATOR
Intervention: pcTBS
Number of subjects: 16
Study: 28368269

Group type: EXPERIMENTAL
Intervention: Probiotic group (n=52) received a multicomponent probiotic formulation of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces boulardii once a day at a dose of 1.25×10^9 CFU from the time of initiation of enteral feeds till discharge
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (n=52) received only breast milk
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 104
Study: 25957978

Group type: EXPERIMENTAL
Intervention: Nasal tube
Number of subjects: 43

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 43
Study: 23713294

Group type: EXPERIMENTAL
Intervention: Wuhuang Tangkangling (decoction daily for 8 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pioglitazone (15 mg x d(‐1) orally once a day) combined with insulin subcutaneous injection
Number of subjects: 100
Study: 21606263

Group type: EXPERIMENTAL
Intervention: Low-dose MDCT and CT enterography with adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-dose MDCT and CT enterography with ASIR
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard-dose 64-MDCT and CT enterography with filtered back projection (FBP)
Number of subjects: 48
Study: 19665833

Group type: EXPERIMENTAL
Intervention: Load-distributing band CPR (LDB-CPR)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 4
Study: 17353340

Group type: EXPERIMENTAL
Intervention: non-Carr-Purcell-Meiboom-Gill (non-CPMG) single-shot fast spin-echo (SS-FSE) sequence
Number of subjects: 24

Group type: COMPARATOR
Intervention: EPI-based sequence
Number of subjects: 24
Study: 15042546

Group type: EXPERIMENTAL
Intervention: Low AGE diet (L-AGE)
Number of subjects: 189

Group type: COMPARATOR
Intervention: High AGE diet (H-AGE)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Comparison of L-AGE and H-AGE groups
Number of subjects: 189
Study: 11941338

Group type: EXPERIMENTAL
Intervention: Extraction orthodontic treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonextraction orthodontic treatment
Number of subjects: 24
Study: 9736563

Group type: EXPERIMENTAL
Intervention: Rufloxacin 200 mg once daily for days 2 to 7
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophylline without rufloxacin
Number of subjects: 12
Study: 7817333

Group type: EXPERIMENTAL
Intervention: Analgesic treatment consisting of water and sucrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 31329516

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus androgen deprivation therapy (ADT)
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus ADT
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1150
Study: 29798096

Group type: EXPERIMENTAL
Intervention: Modified Semont maneuver
Number of subjects: 130

Group type: COMPARATOR
Intervention: Epley maneuver
Number of subjects: 130
Study: 25903286

Group type: EXPERIMENTAL
Intervention: MVMH supplement
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 24108248

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine or bupivacaine (5 mL or less)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine or bupivacaine (10 mL or greater)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Injection volumes of 2.5 and 5 mL
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Injection volumes greater than or equal to 10 mL
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% bupivacaine or ropivacaine
Number of subjects: 142
Study: 21420062

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham EECP
Number of subjects: 42
Study: 19862391

Group type: EXPERIMENTAL
Intervention: PVS extra low viscosity (Panasil Contact Plus)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: PVS medium viscosity (Virtual Monophase)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: PVS low viscosity (Affinis Light Body)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Polyether low viscosity (Permadyne Garant)
Number of subjects: 4

Group type: COMPARATOR
Intervention: All materials
Number of subjects: 4
Study: 16440191

Group type: EXPERIMENTAL
Intervention: Unidimensional RECIST method
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bidimensional WHO method
Number of subjects: 80
Study: 15045806

Group type: EXPERIMENTAL
Intervention: Nurse-led education programme
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Full ankle movement (> 60 degrees) and full mobility (without aid)
Number of subjects: 49
Study: 11231996

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (20 microgram/kg, sc, at 0 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg, iv, at 180 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Insulin levels calculated over 270 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose levels calculated over 270 min
Number of subjects: 6
Study: 9562229

Group type: EXPERIMENTAL
Intervention: Test preparation (desmopressin nasal spray)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reference preparation (desmopressin nasal spray)
Number of subjects: 16
Study: 7876034

Group type: EXPERIMENTAL
Intervention: Conditioning stimulus and testing stimulus (identical auditory clicks) at 500 msec interval
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Count/no-count task introduction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Task-independent suppressing effect of a conditioning stimulus presentation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Task-dependent effect at the P50 range
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Full epoch data inspection
Number of subjects: 20
Study: 2745258

Group type: EXPERIMENTAL
Intervention: Cefotetan 2 g
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cefoxitin 2 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 6
Study: 961473

Group type: EXPERIMENTAL
Intervention: Amino acid infusion during fructose infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of fructose and amino acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fructose infusion without amino acids
Number of subjects: 0
Study: 31542440

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) procedure
Number of subjects: 187
Study: 31727284

Group type: EXPERIMENTAL
Intervention: CMR-first strategy
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: CTA-first strategy
Number of subjects: 207

Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 207
Study: 28806355

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine
Number of subjects: 1301
Study: 25100053

Group type: EXPERIMENTAL
Intervention: Self-reported adherence to FTC/TDF
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pill-count data
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Four adherence measures
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Use of oral contraceptives
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Weeks of time in the study
Number of subjects: 150
Study: 23441589

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy (group 1, n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rigid cystoscopy (group 2, n=40)
Number of subjects: 80
Study: 22082698

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (educational brochure plus activities designed to enhance beliefs about stroke)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard intervention (educational brochure plus activities that were not about stroke)
Number of subjects: 26
Study: 18486235

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5-375 mg daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Lithium 300-2100 mg daily
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 83
Study: 17286342

Group type: EXPERIMENTAL
Intervention: Broad-spectrum treatment (BST) with naltrexone
Number of subjects: 149

Group type: COMPARATOR
Intervention: Motivational-enhancement therapy (MET) with naltrexone
Number of subjects: 149
Study: 14712408

Group type: EXPERIMENTAL
Intervention: Protocol A (single injection of Gd‐BOPTA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Protocol B (two injections of Gd‐BOPTA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both Protocols (without pedal station)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Protocol A
Number of subjects: 80

Group type: COMPARATOR
Intervention: Protocol B
Number of subjects: 80
Study: 10749620

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.3 U/kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 20
Study: 8969390

Group type: EXPERIMENTAL
Intervention: Fentanyl/propofol/nitrous oxide/vecuronium anesthesia with early extubation (group 1A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fentanyl/midazolam/vecuronium anesthesia with late extubation (group 1B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pneumonectomy (group 2)
Number of subjects: 50
Study: 1425615

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram kg‐1 i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6539381

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 30977390

Group type: EXPERIMENTAL
Intervention: Draft addendum E9/R1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case study from the diabetes therapeutic area
Number of subjects: 0
Study: 30716797

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (3 times, every 2 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (5 times, every 2 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall recovery (both groups combined)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Interval between onset of symptoms and therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Presence rate of vertigo
Number of subjects: 90
Study: 26577199

Group type: EXPERIMENTAL
Intervention: Humidified high-flow nasal cannula (HFNC)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard O2
Number of subjects: 303
Study: 24865871

Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS) program
Number of subjects: 199

Group type: COMPARATOR
Intervention: Parent-focused treatment (PFT)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 199
Study: 21104601

Group type: EXPERIMENTAL
Intervention: Student tutors (ST)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Faculty staff sonographer (FS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of improvement between ST and FS
Number of subjects: 46
Study: 19531591

Group type: COMPARATOR
Intervention: LATER subgroup (MENA 14.0 ± 0.7 years)
Number of subjects: 124
Study: 17688760

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ-9)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM)
Number of subjects: 93
Study: 15172464

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Diabetes (as a condition)
Number of subjects: 395
Study: 12238408

Group type: EXPERIMENTAL
Intervention: Enhanced home visitation (cognitive component)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control condition (unenhanced home visitation)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Unenhanced home visitation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Program features (cognitive component)
Number of subjects: 96
Study: 9839777

Group type: EXPERIMENTAL
Intervention: Teril 600 CR tablet
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CBZ 600 granulate
Number of subjects: 3

Group type: COMPARATOR
Intervention: Timonil 600 Retard tablet
Number of subjects: 3
Study: 7862232

Group type: COMPARATOR
Intervention: Typical treatment
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Typical treatment + ganglioside GM1 (100 mg daily for 30 days, i.v. for first 5 days, then i.m.)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Typical treatment + ganglioside GM1
Number of subjects: 98
Study: 2678427

Group type: EXPERIMENTAL
Intervention: Ileal conduit
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Colonic conduit
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Continent caecal reservoir
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Refluxing ureterointestinal anastomosis
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Antirefluxing ureterointestinal anastomosis
Number of subjects: 70
Study: 1094960

Group type: EXPERIMENTAL
Intervention: Halcinonide cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betamethasone valerate cream
Number of subjects: 0
Study: 30267702

Group type: EXPERIMENTAL
Intervention: Fisher technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mohler technique
Number of subjects: 50
Study: 28940312

Group type: EXPERIMENTAL
Intervention: 100 μg LSD administered orally
Number of subjects: 20
Study: 26255517

Group type: EXPERIMENTAL
Intervention: Acupuncture at Yaotongdian (Extra) after massage
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acupuncture at Houxi (SI 3) after massage
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acupuncture at Weizhong (BL 40) after massage
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acupuncture at Chengshan (BL 57) after massage
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acupuncture at Shuigou (GV 26) after massage
Number of subjects: 150
Study: 23817954

Group type: EXPERIMENTAL
Intervention: PICC method (group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CVC method (group A)
Number of subjects: 80
Study: 21633025

Group type: EXPERIMENTAL
Intervention: Oral sitamaquine, 2 mg/kg/day, once a day for 21 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intravenous amphotericin B (AmB), 1 mg/kg every other day for 30 days
Number of subjects: 61
Study: 19250074

Group type: EXPERIMENTAL
Intervention: Optimized VV delay programming (OPT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Simultaneous biventricular stimulation (SIM)
Number of subjects: 48
Study: 16923135

Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulfate three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Identical placebo tablet three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulfate three times daily (after crossover)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Identical placebo tablet three times daily (after crossover)
Number of subjects: 0
Study: 15252069

Group type: EXPERIMENTAL
Intervention: Independent people renting their home
Number of subjects: 6298

Group type: EXPERIMENTAL
Intervention: People living with someone other than spouse renting their home
Number of subjects: 6298
Study: 10857970

Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/day) for 12 weeks
Number of subjects: 27
Study: 9120161

Group type: EXPERIMENTAL
Intervention: Ambulatory training program
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (physically inactive)
Number of subjects: 9
Study: 1440306

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine 40 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrendipine (20 mg once or twice a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg twice a day
Number of subjects: 0
Study: 3700308

Group type: EXPERIMENTAL
Intervention: Exercise anticipation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mental arithmetic tasks
Number of subjects: 15
Study: 29420221

Group type: EXPERIMENTAL
Intervention: Adjuvant transarterial chemoembolization (TACE)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control (no adjuvant treatment)
Number of subjects: 280
Study: 26762911

Group type: EXPERIMENTAL
Intervention: BFD (standard dose)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: BFD-LD (low dose)
Number of subjects: 182

Group type: COMPARATOR
Intervention: PES (first-generation paclitaxel-eluting stents)
Number of subjects: 182

Group type: COMPARATOR
Intervention: BFD, BFD-LD, PES (5-year outcomes)
Number of subjects: 182
Study: 25579140

Group type: EXPERIMENTAL
Intervention: Lactol probiotic
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no lactol)
Number of subjects: 30
Study: 22999589

Group type: EXPERIMENTAL
Intervention: Bronchoscopic argon plasma coagulation plus routine antituberculosis chemotherapy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Routine antituberculosis chemotherapy
Number of subjects: 115
Study: 20801496

Group type: EXPERIMENTAL
Intervention: 150 mg dabigatran
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: 110 mg dabigatran
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study: 18254486

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray, 2 sprays per nostril twice daily
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray, 2 sprays per nostril once daily
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Combination of azelastine nasal spray and fluticasone nasal spray
Number of subjects: 151
Study: 17006062

Group type: EXPERIMENTAL
Intervention: Morphine administration postoperatively
Number of subjects: 22
Study: 14746666

Group type: EXPERIMENTAL
Intervention: Program to enhance health literacy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 81
Study: 10404919

Group type: EXPERIMENTAL
Intervention: Chronic Care Clinics intervention (96 patients)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Usual care (73 patients)
Number of subjects: 169
Study: 8867642

Group type: EXPERIMENTAL
Intervention: 3% diclofenac/2.5% sodium hyaluronate topical gel, applied 4 times daily for 2 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo gel lacking the active substance
Number of subjects: 119